News + Insights

For the past several years, the story of employer-sponsored glucagon-like peptide-1 (GLP-1) coverage has been one of expansion, with plan sponsors adding weight management benefits, employees pressing for access and headlines noting who covers what. Heading into 2027, that story is changing. Coverage isn’t disappearing, but the default position among large employers has shifted from a general trend toward expanded access to deliberate strategies with eligibility criteria, program requirements and a harder look at whether the cost of these treatments is worth the investment.

The stakes haven’t gotten smaller. Employee demand for these drugs remains high, and so does the cost of paying for them.

Nearly 8 in 10 employers now say GLP-1s are driving up their overall healthcare costs, according to a survey by the Business Group on Health, and there’s no consensus playbook for managing that pressure. What’s changed is the framing. Most large employers settled the question of whether to cover GLP-1s years ago. The work of plan designs is figuring out how to cover them responsibly.

This article examines where coverage stands today, why the outlook is shifting heading into 2027 and how employers are redesigning access rather than abandoning it.

Where Coverage Stands Today

Employer coverage already looks uneven, and the gap between diabetes and weight management coverage is the clearest evidence that the market is still finding its footing. While most employers cover GLP-1s for diabetes, Business Group on Health’s (BGH) 2026 survey of large employers found that 67% currently cover GLP-1s specifically for weight management. This is a notably narrower benefit than diabetes coverage, where most large plans cover treatment for qualifying Type 2 diabetes.

The gap between diabetes and weight management coverage isn’t surprising on its own; diabetes coverage has a longer track record and a clearer clinical case that employers have already accepted. What’s less settled is how far employers are willing to go on the weight management side. In fact, Mercer reported that 6% of large employers dropped GLP-1 coverage altogether this past year.

This figure is a reminder that some employers are still pulling back rather than expanding. That pullback isn’t hypothetical. Cigna, notably, stopped covering GLP-1 weight-loss treatments for its own employees in July 2026, telling staff they could purchase the medications elsewhere. This is a visible example of an employer deciding the cost of the ledger outweighs the retention and productivity case for keeping the benefit open-ended.

While GLP-1s are expensive treatments, cash-pay options for employees outside of their group health coverage are becoming more viable and popular.

GLP-1 medications are now feeling the effects of the Trump administration’s most-favored-nation (MFN) policy, which seeks to bring U.S. drug prices in line with the lowest rates paid by other developed nations. Following a November 2025 agreement with Novo Nordisk and Eli Lilly, patients can purchase GLP-1s through the TrumpRx platform for $150 to $400 per month, covering both oral and injectable options.

Medicare followed suit in July 2026, introducing injectable weight-loss medications for eligible members at $245 per month with copayments capped at $50. As these self-pay alternatives gain traction, they may shape how employers and employees, whether or not they have group health coverage, approach coverage decisions heading into 2027.

Early evidence suggests GLP-1 medications can reduce certain medical costs, particularly hospitalizations tied to diabetes- and obesity-related complications; however, for most employers, those savings are outweighed by the average annual drug cost of roughly $6,000 per active participant. GLP-1s can deliver meaningful clinical benefits, including weight loss, improved metabolic control and reduced cardiovascular risk, but translating those benefits into measurable financial returns can be unclear.

In addition, GLP-1s can impact employee attraction, retention and productivity, though these effects are difficult for employers to measure. Higher medication adherence drives better outcomes but also accelerates claims costs, and the average U.S. worker tenure of roughly four years is often too short a window to recoup drug expenses. For most employers, their return on investment will depend heavily on workforce-specific factors, making a one-size-fits-all coverage decision difficult to justify on financial grounds alone.

Why 2027 Looks Different

If 2026 was the year employers started asking hard questions, 2027 is shaping up to be the year those questions get answered. The BGH’s February–March 2026 survey of 105 large employers found that among those currently covering GLP-1s for weight management, 72% intend to maintain that coverage in 2027, while 10% said they are unlikely to. The remaining 18% are still undecided. That’s a meaningfully softer commitment than blanket coverage implies, and BGH’s own analysis notes that employers who don’t cover weight management GLP-1s today are unlikely to start.

Layered on top of that uncertainty is the arrival of oral GLP-1 formulations, including an oral version of Wegovy and Eli Lilly’s Foundayo, which removed the biggest barrier to adoption for people who were uncomfortable with weekly injections.Employers see this coming, with the BHG survey reporting that 87% anticipate oral availability will drive higher demand, while only 9% expect it to lower prices.

That combination of growing demand, flat or rising prices and no structural fix in sight is why nearly 8 in 10 employers have pushed GLP-1 coverage decisions up to executive leadership, according to the BHG survey. This isn’t a routine benefits renewal anymore; it’s a budget-line conversation happening in the C-suite.

The Strategic Shift From Blanket Coverage to Managed Access

Rather than retreating outright, most employers are redesigning their coverage. The strategies showing up most often in 2027 plan design include:

• Lifestyle program participation as a condition of coverage—Employees increasingly need to enroll in a structured weight management or lifestyle program to access or maintain GLP-1 coverage, not just fill a prescription.
• Biometric eligibility criteria replacing self-reported qualifications—Objective clinical data, body mass index (BMI) thresholds, comorbidities and lab values are replacing self-attestation as the gatekeeper for who qualifies.
• Provider and formulary restrictions—Employers are narrowing which providers can prescribe GLP-1s and trimming which specific medications are covered, tightening a benefit that used to be broadly open.
• Step therapy and prior authorization—Many employees are required to try lower-cost alternatives first or obtain upfront sign-off before a GLP-1 prescription is approved, adding a clinical review layer that focuses on allocating spend to patients who need it most or have reviewed less costly treatments.
• Direct-to-employer platforms—Programs such as GoodRx Employer Direct and Eli Lilly’s Employer Connect let employers subsidize manufacturer-discounted prices for drugs like Zepbound and Wegovy outside the traditional insurance formulary. This is a way around the pricing structures that several benefits leaders describe as a major driver of the affordability gap between what employers pay and cash-pay benchmarks.

Notably, most employers aren’t fully shifting costs onto employees to make this work. The majority (83%) still apply the same cost-sharing structure to GLP-1s as they do to other medications, according to the BGH survey. The recalibration is happening on the eligibility and management side, not the copay side (at least for now).